Neuphoria Therapeutics Inc. NEUP 深 沪
已收盘 02-06 16:00:00 美东时间
4.01
+0.015
+0.38%
华盛通- 最 高4.095
- 今 开3.96
- 成交量 2.33万股
- 最 低 3.96
- 昨 收 3.995
- 总市值 2156.31万
- 52周最高 21.4004
- 市盈率 静 --
- 换手率 0.43%
- 52周最低 3.645
- 委 比 -7.83%
- 总股本 537.73万
- 历史最高 21.4004
- 量 比 0.85
- 振 幅 3.38%
- 历史最低 2.90
- 每 手 1
- 风险率 3.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 高盛上调梅西百货目标价至22美元！ 摩根大通上调美国铝业公司目标价至45美元
今日重点评级关注：Stifel：维持X4 Pharmaceuticals"买入"评级，目标价从7.5美元升至10美元；花旗：维持UP Fintech Holding"买入"评级，目标价从17.4美元升至17.5美元
2025-12-08 08:34
Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan To Protect Integrity Of Process; Board Declares Dividend Of One Preferred Share Purchase Right For Each Outstanding Share Of Co
Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders,today announced that its Board of Directors
2025-10-28 04:53
Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process
Neuphoria Therapeutics announced its Board has adopted a limited-duration stockholder rights plan to safeguard against rapid accumulation of its shares by investors. The plan aims to protect shareholder interests, ensure fair participation in strategic reviews, and prevent control without a premium. It does not hinder the Board from exploring strategic alternatives. The rights will trigger if any entity gains 15% ownership without Board approval,...
2025-10-27 20:29
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers iBio (NASDAQ:IBIO) stock increased by 28.8% to $1.15 during Monday's a...
2025-10-21 05:08
Neuphoria's AFFIRM-1 Trial For Social Anxiety Fails To Meet Endpoints; Company Initiates Strategic Review
AFFIRM-1 trial did not meet primary endpoint or secondary endpointsCompany to conduct strategic review of portfolio and business operationsBURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc.
2025-10-21 04:19
Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder
Neuphoria Therapeutics Inc. announced that its AFFIRM-1 Phase 3 trial for BNC210 in treating social anxiety disorder (SAD) did not meet its primary or secondary endpoints. The company plans to discontinue further development of the SAD program and evaluate next steps for BNC210 in post-traumatic stress disorder (PTSD). Neuphoria will conduct a strategic review of its operations and portfolio. The company has $14.2 million in cash and expects to f...
2025-10-20 20:15
美股大行评级 | 潜在涨幅208.48%！HC Wainwright & Co.上调Microbot Medical目标价至12美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Microbot Medical"买入"评级，目标价从9美元升至12美元；Maxim Group：维持Neuphoria Therapeutics"买入"评级，目标价从18美元升至35美元
2025-09-12 12:53
Maxim Group Maintains Buy on Neuphoria Therapeutics, Raises Price Target to $35
Maxim Group analyst Jason McCarthy maintains Neuphoria Therapeutics (NASDAQ:NEUP) with a Buy and raises the price target from $18 to $35.
2025-09-11 22:30
Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)
Neuphoria Therapeutics announced the achievement of 332 participants in the AFFIRM-1 Phase 3 trial for BNC-210, a breakthrough acute treatment for social anxiety disorder (SAD). BNC-210, designed to rapidly alleviate anxiety without sedation or cognitive impairment, has received FDA Fast Track designation. The trial evaluates its safety and efficacy through a public speaking challenge and uses multiple metrics to measure anxiety reduction. With t...
2025-09-04 11:00
Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Neuphoria Therapeutics Inc. announced that its CEO, Spyros Papapetropoulos, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025, in New York. The presentation will be available online starting September 5. Neuphoria, a clinical-stage biotech company, is developing therapies for neuropsychiatric disorders, including its lead drug candidate, BNC-210, for the treatment of social anxiety disorder and P...
2025-08-28 20:05
